Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. GlaxoSmithKline plc
  6. Summary
    GSK   GB0009252882

GLAXOSMITHKLINE PLC

(GSK)
  Report
Real-time Estimate Quote. Real-time Estimate Cboe Europe - 09/27 07:07:25 am
1391.8 GBX   +0.27%
09/24GLAXOSMITHKLINE ( '') (FORM 6 K : GlaxoSmithKline plc (the 'Company') (Form 6-K)
PU
09/24European ADRs Move Lower in Friday Trading
MT
09/24GLAXOSMITHKLINE : UBS sticks Neutral
MD
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
09/21/2021 09/22/2021 09/23/2021 09/24/2021 09/27/2021 Date
1419(c) 1429(c) 1414(c) 1388(c) 1393 Last
5 230 245 6 407 669 4 424 302 6 869 580 1 070 990 Volume
+1.07% +0.70% -1.05% -1.84% +0.36% Change
More quotes
Estimated financial data (e)
Sales 2021 33 307 M 45 607 M 45 607 M
Net income 2021 3 857 M 5 281 M 5 281 M
Net Debt 2021 20 885 M 28 598 M 28 598 M
P/E ratio 2021 18,2x
Yield 2021 5,76%
Sales 2022 35 077 M 48 031 M 48 031 M
Net income 2022 4 719 M 6 462 M 6 462 M
Net Debt 2022 19 408 M 26 576 M 26 576 M
P/E ratio 2022 15,2x
Yield 2022 3,84%
Capitalization 69 468 M 94 962 M 95 123 M
EV / Sales 2021 2,71x
EV / Sales 2022 2,53x
Nbr of Employees 94 066
Free-Float 92,2%
More Financials
Company
GlaxoSmithKline PLC is a global healthcare company. The Company operates through two segments: Pharmaceuticals and Vaccines. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. The Company makes a range of prescription medicines and vaccines products. The Pharmaceuticals business... 
Sector
Pharmaceuticals
Calendar
10/27Earnings Release
More about the company
Ratings of GlaxoSmithKline plc
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about GLAXOSMITHKLINE PLC
09/24GLAXOSMITHKLINE ( '') (FORM 6 K : GlaxoSmithKline plc (the 'Company') (Form 6-K)
PU
09/24European ADRs Move Lower in Friday Trading
MT
09/24GLAXOSMITHKLINE : UBS sticks Neutral
MD
09/24GLAXOSMITHKLINE : Federal Circuit Vacates Judgment, Reinstates Jury's Verdict Of Induced I..
AQ
09/23GLOBAL MARKETS LIVE : Valneva,Boeing, Facebook, Kubota, Otis...
09/23Activist Bluebell Capital Takes Small Stake in GSK to Push for Board Change -FT
DJ
09/23GLAXOSMITHKLINE : Survey Shows More People In Favor Of Vaccinations After COVID-19
MT
09/22GLAXOSMITHKLINE : CEO Faces Additional Pressure as Bluebell Joins Elliott in Demanding Man..
MT
09/22GLAXOSMITHKLINE : Activist investor Bluebell takes stake in GSK to challenge chief exec
AQ
09/22Bluebell Capital Takes Stake in GlaxoSmithKline to Shake-up the Company’s Leadership
CI
09/22GLAXOSMITHKLINE : Bluebell Capital Says Believes GSK Should Address Leadership For ôNew GS..
RE
09/22Bluebell capital says believes gsk's emma walmsley would have been a very credible cand..
RE
09/22Activist investor Bluebell takes stake in GSK
RE
09/22GLAXOSMITHKLINE ( '') (FORM 6 K : GlaxoSmithKline plc (the 'Company') (Form 6-K)
PU
09/22GLAXOSMITHKLINE : Changing attitudes to vaccination after the COVID-19 pandemic could incr..
PU
More news
News in other languages on GLAXOSMITHKLINE PLC
09/24Les ADR européens en baisse vendredi
09/23ASTRAZENECA : la pharma se lance dans l'ARN messager avec VaxEquity
09/23EN DIRECTO DESDE LOS MERCADOS : Metrovacesa, Capgemini,, GTT, Com, Facebook, Boeing, China..
09/23MADRID STOCK EXCHANGE : Dicen que la Fed ha hablado
09/23STOCK MARKET PARIS : Il paraît que la Fed a parlé
More news
Analyst Recommendations on GLAXOSMITHKLINE PLC
More recommendations
Chart GLAXOSMITHKLINE PLC
Duration : Period :
GlaxoSmithKline plc Technical Analysis Chart | GSK | GB0009252882 | MarketScreener
Technical analysis trends GLAXOSMITHKLINE PLC
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 1 388,00 GBX
Average target price 1 604,94 GBX
Spread / Average Target 15,6%
EPS Revisions
Managers and Directors
Emma N. Walmsley Chief Executive Officer & Executive Director
Iain James Mackay Chief Financial Officer & Executive Director
Jonathan Richard Symonds Non-Executive Chairman
Karenann K. Terrell Chief Digital & Technology Officer
Hal V. Barron Executive Director & Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
GLAXOSMITHKLINE PLC3.43%94 962
JOHNSON & JOHNSON4.44%432 675
ROCHE HOLDING AG10.16%321 605
PFIZER, INC.19.37%246 358
NOVO NORDISK A/S50.45%231 485
ELI LILLY AND COMPANY37.22%210 037